Latest News

CHAIN Awarded £0.5M Grant Funding to Develop Healthcare Platform

CHAIN Biotech has been awarded £0.5M grant funding from Innovate UK, the UK’s innovation agency, to expand its range of biotechnology products. Building on a successful synthetic biology program, are centered on enhancing and extending the capability of CHAIN’s proprietary Clostridium spore-based delivery platform for therapeutic and specialty chemical applications. A two-year project will focus on the development of novel therapeutic peptides targeting gut-related disease. CHAIN has successfully demonstrated the use of Clostridium to deliver small molecules to the gut....
Read More

CHAIN Appoints New Board Members

CHAIN welcomes to its Board of Directors the recent appointment of Dr Mike McDonald and Peter McPartland as Non-Executive Directors. The appointments follow CHAIN’s successful seed investment round, led by Rainbow Seed Fund, earlier this year. Dr McDonald, a physician, brings 30 years of experience in US and European drug development. He has leadership and management experience with major therapeutics and pharmaceuticals companies. His past appointments include VP of Global Clinical Research and Medical Affairs with Eli Lilly, Chief Medical...
Read More

CHAIN Finalists in Biotechnology Awards

CHAIN Biotechnology is proud to announce that it is a finalist in two competitions celebrating excellence in the fields of biotechnology and life sciences. CHAIN has made it to the final round of the OBN Awards for “Best Emerging UK Synthetic Biotech” and the Institute of Chemical Engineering (IChemE) Global Awards for “Best Business Start-Up”. The OBN Awards, now in their 8th year, celebrate innovation and achievement across the UK life sciences industry. The category of Best Emerging UK Synthetic...
Read More

CHAIN Celebrates Successful ‘Chiral Chemical Synthesis in Clostridia’ Study

LONDON, UK, 10 AUGUST 2016 -- CHAIN Biotechnology Ltd has successfully completed a 12-month research project entitled “Chiral Chemical Synthesis in Clostridia”. The research was supported by a grant from Innovate UK, the UK’s innovation agency. Specifically, CHAIN has demonstrated a new way to change the stereochemistry of intracellular metabolism in Clostridia bacteria, resulting in the re-direction of carbon flow towards R-chiral chemicals rather than the natural S-form. This change in stereochemistry, referred to as the “Chiral Switch™”, resulted in...
Read More

CHAIN Obtains Grant Funding For Collaborative Projects

June 11, 2016 – London, UK. CHAIN Biotechnology Ltd has won grant funding for two new research collaborations which advance CHAIN’s synthetic biology platform and microbial engineering capabilities. The first project – called PUFA (polyunsaturated fatty acids) – sees CHAIN partnering with the University of Nottingham. PUFA will use advances in synthetic biology to develop microbial fermentation on methane gas to produce a sustainable source of valuable Omega 3 fatty acids which are currently harvested from fish oil. This ground-breaking...
Read More

CHAIN Welcomes New Starters

CHAIN has hired two new world class scientific team members to expand its role in Clostridia Technology and cement its position in world-leading synthetic biology. Dr Janina Koelschbach comes to CHAIN from the Biofilm Centre at the University of Duisburg-Essen, Germany, where she set up a laboratory for anaerobic research. She earned her PhD in Microbial Biochemistry from the Technical University of Munich working in the field of anaerobic microbial degradation of polycyclic aromatic hydrocarbons. Her research involved synthetic biology...
Read More

CHAIN Secures Seed Funding and Appoints New Board Members

London, UK, 23 December, 2015 CHAIN has successfully completed its first round of seed funding last month with the support of a consortium of business angels based in the UK. Business angels are investors who bring expertise and provide start-up capital.  CHAIN will use the funds to strengthen its unique technology platform based on the development of advanced microbes for the production of high value chemicals. Board Appointments CHAIN also welcomes Robert Rickman and Paul Green to the Board of Directors. Mr...
Read More

CHAIN Celebrates Feasibility Study Success at Collaboration Nation

CHAIN Biotech has successfully completed a feasibility study into altering bacterial metabolism to produce novel chemicals. The four-month project was funded by Innovate UK, the UK’s innovation agency, and performed at Imperial College, London. In nature, some chemicals exist in two forms which are mirror images of each other, like our left and right hands – the S and R forms. Chemical synthesis often results in a racemic mixture which contains both forms. However, one form may have a detrimental...
Read More

CHAIN Wins Business Interaction Voucher with University of Nottingham

CHAIN Biotechnology has been awarded a £5,000 Business Interaction Voucher in partnership with the University of Nottingham’s Synthetic Biology Research Centre (SBRC). The Voucher, awarded by the Plants to Products (P2P) Network in Biotechnology and Bioenergy and funded by the BBSRC, will fund a project to develop a multi-parallel bioreactor screening method for anaerobic bacteria. Important Anaerobes Anaerobes like Clostridium are capable of producing a variety of useful chemicals including the biofuel butanol and the solvent acetone. Research into developing novel strains of...
Read More

CHAIN launches a new grant funded research project

CHAIN has been awarded £180K from InnovateUK for a project focused on the production of high-value chiral chemicals using fermentation at costs competitive with current chemical synthesis. This 12 month feasibility project starts on the 1st August 2015 and uses synthetic biology and microbial fermentation of renewable feedstocks to address key environmental and sustainability concerns. Success on this project will enable us to exemplify our anaerobic chassis and fermentation platform for advanced Biotechnology products and applications.  
Read More